ShareJunction - Stock Forum Messages

Biosensors

Is Biosensors a good buy?

bro, i am born in 1980..

bengster68 ( Date: 28-Jun-2008 21:56) Posted:

JJ, i thought you old man liao. How come now then get married??? Third or fourth one har? Smiley

Maybe BIG's AGM is on your wedding day. Ask your "brothers" to go BIG's AGM and "Cho Luan" like Japanese Yakuza. Maybe BIG will give them some ang pow and make peace. Anyway, congratulations to you JJ. Wedding ring is also of suffer"ring". Some are dying to get in, but a lot dying to get out Smiley

Walau BIG so "Kiam Kar Nar" one, $2,600 for engineer??? Now construction site ah beng foreman also making around $4,500 to 5,000 liao. I know already, their manufacturing process is so automated, the process engineer just press machine start / stop button can already.

Saw quite a number of positions as well in Straits Times today..

Highest post was for "Manager, Regulatory ..." and looking for person with Life Sciences degree to tackle regulatory issues.

judging from the job openings, it seems like Production (Chemist, QA and QC), Sales & Regulatory are the key focus areas..

Sounds +ve to me if they are ramping up in these areas...

jackjames ( Date: 28-Jun-2008 11:01) Posted:

Responsibilities:

Responsible for the improvement of Quality System, CAPAs, Complaints, Audits, Non-Conformance Reports.
Conducts quality assurance audits for critical control points and key elements for the systems related to product release, quality assurance, employee training and competency assessment.
To review and approve documents to ensure compliance with statutory, regulatory, procedures requirements as applicable prior to its implementation at site.
Prepare, review and revise all GMP documents such as QC records, quality procedures (SOPs), specifications and sampling plans.

Checked from ESC website and got this info... here comes the LEADERS results on 1st Sept 2008! Long way to go man..

Presenter Information

Title:	Professor
Initials:	S
First Name:	Stephan
Last Name:	Windecker

Session(s) / Presentation(s) List

Date

Time Slot

Title

Room

Presentation Start Time

Presentation Title

Final Prog. Number

Details

01 Sep 2008

11:00-12:30

Hot Line II

Munich - Zone A4

12:12

LEADERS - Limus Eluted from A Durable versus Erodable stent coating (Randomized Comparison of a biolimus-A9 eluting stent with a sirolimus-eluting stent for percutaneous coronary intervention.

0

JJ, i thought you old man liao. How come now then get married??? Third or fourth one har? Smiley

Maybe BIG's AGM is on your wedding day. Ask your "brothers" to go BIG's AGM and "Cho Luan" like Japanese Yakuza. Maybe BIG will give them some ang pow and make peace. Anyway, congratulations to you JJ. Wedding ring is also of suffer"ring". Some are dying to get in, but a lot dying to get out Smiley

Walau BIG so "Kiam Kar Nar" one, $2,600 for engineer??? Now construction site ah beng foreman also making around $4,500 to 5,000 liao. I know already, their manufacturing process is so automated, the process engineer just press machine start / stop button can already.

do let us know the AGM date and venue, if time is allowed, i will go... just want to know their vision and management power...

kanasai, in jobstreet, they offer S$2600-3000 paid for process engineer, that's too low la.. come on..

next month is my big day... wedding day... hee..

Har BIG so "Tao" one ah?? Maybe they know you are JJ from SJ forum and they ban you first? Smiley

You can consider go to their AGM next month and "Cho Luan". I think its held at a 5 star hotel. Got buffett some more. KNN no dividend and share price cannot perform so must eat some thing back from them.

I did apply for Production Manager last time, but no interview lei...

bengster68 ( Date: 28-Jun-2008 12:00) Posted:

Hey Jackjames, how about you apply to work in BIG's DES production QC and give us update on their production? BIG stated earlier that their Kaki Bukit production facilities has current production capacity of 10,000 Biomatrix units per month with capacity for further expansion in future. I think after LEADERS trial, BIG may need to start planning to expand their production capacity liao.

Super low restenosis rate, near zero TLR rates and zero late-thrombosis and very late-thrombosis cases. Biomatrix has very obvious potential to become the next market leader. All they need is ang moh branding, very extensive sales / distribution channels and Biomatrix's will reach market leader position.

Boston Scientific: Hurry To The Pre-4th of July Sale On Stents!?

FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."

Taxus is the name of Boston Scientific's drug-coated stent, a tiny wire mesh cylinder that props open clogged arteries. This isn't all that surprising given the fact that Medtronic recently entered the drug-coated stent market, busting up the duopoly of BSX and Johnson & Johnson.

And any day now, there could be a fourth player. Some analysts still expect Abbott to win Food and Drug Administration approval of its drug-coated stent Xience by the end of this month. But at least a couple of them, including FBR's Warren, now believe approval could come later rather than sooner. The analyst quotes an interventional cardiologist (the docs who put in stents) who says ABT's sales reps are telling him (the doc) that Xience will be launched in the fourth quarter.

JPMorgan's medical device guy Mike Weinstein emailed me to say that Abbott is apparently telling him to continue to look for approval here in Q2. Under the odd terms of BSX's acquisition of Guidant--it had to sell pieces of it to ABT--Boston Scientific would get to sell the Xience stent, but using the brand name Promus. Most analysts think Xience will quickly become the stent of choice because tests have shown it may have a lower rate of blood clots forming down the road and doctors think it's easier to put in.

Warren says his expert who works here in the New York area indicated that drug-coated stent prices have fallen 21 percent over the past year to the $1,100 BSX is charging in its bundling deal regardless of how many stents a cath lab (the highly profitable unit of a hospital where stent procedures are done) might buy. FBR makes a market in BSX.

I've left a landline and mobile voicemail and sent an email to BSX's main spokesman to try to confirm the FBR report. Usually I get a quick reply, but it's vacation season. And in the past the company hasn't commented outside of an earnings press release or conference call on current pricing.

UPDATE: So, I did hear back via email from BSX spokesman Paul Donovan who, as I suspected he would, wrote, "We typically don't comment on price beyond list price."

*** A new strategy by BSX to sell their worse performing DES proven in so many RCTs by slashing their selling price. This strategy may work because their clients (doctors/ hospitals) are concerned on how much they can make per stent. If doctors/ hospitals can make more by implanting Taxus into patients, they may choose profits over patients well-being or clinical trial data. Doctors will continue to tell patients "Taxus has the track record" bullsh.it. After all, Taxus is an approved DES and when something bad happens, you cannot fault the doctor. You can't blame the product because products come with risks and they are approved for use. Dirty business going on behind all these medical business.

Hey Jackjames, how about you apply to work in BIG's DES production QC and give us update on their production? BIG stated earlier that their Kaki Bukit production facilities has current production capacity of 10,000 Biomatrix units per month with capacity for further expansion in future. I think after LEADERS trial, BIG may need to start planning to expand their production capacity liao.

Super low restenosis rate, near zero TLR rates and zero late-thrombosis and very late-thrombosis cases. Biomatrix has very obvious potential to become the next market leader. All they need is ang moh branding, very extensive sales / distribution channels and Biomatrix's will reach market leader position.

Responsibilities:

Responsible for the improvement of Quality System, CAPAs, Complaints, Audits, Non-Conformance Reports.
Conducts quality assurance audits for critical control points and key elements for the systems related to product release, quality assurance, employee training and competency assessment.
To review and approve documents to ensure compliance with statutory, regulatory, procedures requirements as applicable prior to its implementation at site.
Prepare, review and revise all GMP documents such as QC records, quality procedures (SOPs), specifications and sampling plans.

Assistant Manager, Quality Assurance
(Kaki Bukit)

Responsibilities:

Requirements:

Interested applicants, please email full resumes to hrivp@biosensors.com

Candidate must possess at least a Bachelor's Degree in relevant field or equivalent.
At least 5 year(s) of working experience in the related field is required for this position.
Candidates must be familiar with ISO 13485 or FDA regulations for drug or devices, quality system for medical devices, complains handling, auditing, CAPAs and non-conforming material systems.
Ability to perform internal audits, implement quality systems.
Excellent Interpersonal and communication skill
Leadership exposure is required.

Responsible for the improvement of Quality System, CAPAs, Complaints, Audits, Non-Conformance Reports.
Conducts quality assurance audits for critical control points and key elements for the systems related to product release, quality assurance, employee training and competency assessment.
To review and approve documents to ensure compliance with statutory, regulatory, procedures requirements as applicable prior to its implementation at site.
Prepare, review and revise all GMP documents such as QC records, quality procedures (SOPs), specifications and sampling plans.

wah, thats will only see some lights after Olympics??? eat grass alrdy.

1)This is the 2nd 50% purchase that subject to authority approval. In the may Q4 briefing, CEO seems to be very confidence that the approval is on the way. The delay is due to the authority in the midst handling the castastrophic natural disastor and preparing for the Olympics

Pardon me for asking:

1) Is this purchase of 30% & 20% into JWMS is the other half of the 50% that is still pending subject to the authority for approval ??? Or was this for the first 50% that was announced earlier on.

2) So with this SGM, is it a signal that the second half purchase of 50% is already given the green to be sold to BIG or is it BIG is just doing the due diligence to get the in principle approval for this resolution to be passed first so that when the deal is clear by the authority, everything will just fall into the right places and BIG will own 100% of JWMS.

Anyone can shed some lights on this will be very much appreciated. Thank you.

Vested too.

those vested, pse attend the AGM loh. not yet receive the notice yet. a bit slow, AK hv rcv SIA n Stel this week leow.

Biosensors announced SGM/AGM on 22nd July 08 to approve the resolution to issue 120m shares for purchase of 30 % of JWMS from Shandong Weigao, subject to approval in-principle from SGX, and a further 40m shares, pursuant to the put option agreement with Weigao to buy a further 20 % in JWMS, subject to Shandong Weigao exercising the put option.

For futher details, refer to announcement in SGX.

J&J's Heart Stent Cut Need for Repeat Treatments, Study Says 2008-06-24 16:00 (New York) By Alex Nussbaum June 24 (Bloomberg) -- Johnson & Johnson's drug-coated heart stent cut the need for repeat surgeries to unclog arteries by 18 percent since the device was introduced in 2003, while death rates after two years were similar, researchers said. The study compared patients who had heart procedures in years when only bare metal stents were available and those treated with the drug-coated devices after they were approved in 2003. The research is published in tomorrow's Journal of the American Medical Association. Sales of drug-coated stents such as Johnson & Johnson's Cypher and Boston Scientific Corp.'s Taxus plunged 40 percent last year, after a 2006 study suggested the tiny metal sleeves may cause more fatal clots than their bare-metal predecessors. The numbers have rebounded as more recent research dispelled fears, and the JAMA study provides more reassuring results for doctors. ``We can detect no adverse consequence to the health of the population'' using drug-covered stents, a group led by doctors from Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, wrote in the study. Almost 23 percent of patients treated before drug-covered stents reached the U.S. market in 2003 needed follow-up procedures to reopen blood vessels, compared with 19 percent treated after J&J's Cypher went on sale in 2003, the data showed. Fewer Bypasses Those receiving drug-coated stents needed fewer bypass surgeries or other procedures, compared with the bare-metal group. In both eras, 8.4 percent of patients died within two years after receiving the stent. More than 870,000 patients will receive drug-coated stents this year, according to MDRxFinancial, a New York firm that analyzes the health-care industry. Stents are inserted in arteries after they've been cleared of blockages. Cypher, Taxus and rivals made by Abbott Laboratories and Medtronic Inc. are coated with drugs to prevent the growth of tissue that could re- clog the vessels. The Dartmouth study examined the progress of 67,000 Medicare beneficiaries who received stents between 2002 and 2005. While it looked only at people receiving Cypher, the first drug stent sold in the U.S., its results are likely applicable to other devices as well, said David Malenka, a Dartmouth cardiologist and lead author on the paper. While the stents may raise the risk of clots by a ``very small'' amount, ``that risk is more than counterbalanced by the fact that if you have a drug eluting stent, you're less likely to need a second procedure,'' Malenka said in a telephone interview. ``Those second procedures, while they're fairly safe, are not risk free.'' Comparison The study compared the progress of 39,000 people who received stents before March 2003, when only bare-metal versions were available, with 28,000 who had surgery after that point. Drug-coated stents don't make sense for everyone, Malenka said. The fear of clotting, or ``late stent thrombosis,'' means patients have to take blood thinners. That can be a problem for those at high risk for bleeding or people who may need other operations soon after getting a stent. ``The whole concern about late stent thrombosis has led to improvements and important work on stent design and a richer discussion between patients and physicians about the risk and benefits,'' Malenka said. ``We know more now.'' --Editors: Angela Zimm, Robert Greene To contact the reporter on this story: Alex Nussbaum in New York +1-212-617-5406 or anussbaum1@bloomberg.net. To contact the editor responsible for this story: Reg Gale at +1-212-617-2563 or Rgale5@bloomberg.net JNJ <Equity> CN BSX <Equity> CN

yip got strong support.

ha ha at least 2 forumers were watching EU soccer match. unable to wake up to follow the match.

this counter is showing strong support so far at current price region. maybe a good sign

tks for all the sifus' invaluable posting. hope this burger will grow gradually with strength.

Login Register

Is Biosensors a good buy?